Form 4: Enliven CMO Exercises Options, Sells Shares

Enliven Therapeutics' Chief Medical Officer, Helen Louise Collins, exercised stock options and sold 40,000 shares of common stock under a pre-arranged trading plan.

Summary

• Helen Louise Collins, Chief Medical Officer of Enliven Therapeutics, Inc. (ELVN), executed transactions on March 25, 2026.
• Collins exercised stock options to acquire 40,000 shares of common stock at an exercise price of $2.48 per share.
• Concurrently, Collins sold 40,000 shares of common stock at a weighted average sale price of $35.1006 per share, with individual trades ranging from $35.00 to $35.25.
• These transactions were conducted pursuant to a Rule 10b5-1 trading plan, which was adopted by Collins on October 19, 2025.
• Following these reported transactions, Collins directly holds 25,000 shares of common stock, which are Restricted Stock Units (RSUs).
• Collins also beneficially owns 136,268 stock options after the exercise.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, typical for executive compensation and liquidity management under a pre-arranged trading plan, rather than a signal of new sentiment regarding the company's performance.

Positives

• The sale price of $35.1006 per share represents a significant gain over the option exercise price of $2.48 per share, indicating a profitable transaction for the insider.
• The transactions were executed under a Rule 10b5-1 trading plan, suggesting a pre-scheduled and non-discretionary sale rather than a reaction to immediate company news.

Negatives

• An insider sale, even if pre-planned, reduces the direct equity ownership of a key executive, which can sometimes be viewed with caution by investors.

Industry Context

StockSavvy.ai notes that insider transactions, particularly sales, are routinely monitored by investors for signals regarding management's confidence. However, sales executed under a Rule 10b5-1 plan are often pre-scheduled for liquidity or diversification purposes and may not reflect new discretionary sentiment about the company's immediate prospects.

Stakeholder Impact

• Shareholders: The sale, even if pre-planned, slightly reduces the Chief Medical Officer's direct equity stake, which some investors might interpret as a minor reduction in insider alignment, though this is often mitigated by the existence of a Rule 10b5-1 plan.

Key Dates

Recommendation

The insider transaction, while a sale, was executed under a pre-established Rule 10b5-1 trading plan. This suggests it is a routine liquidity event or part of a diversification strategy rather than a reflection of new negative sentiment about the company's prospects. Therefore, it does not provide a strong signal for a change in investment thesis, warranting a 'hold' recommendation.

Keywords

Enliven Therapeutics, ELVN, Form 4, Insider Trading, Stock Option Exercise, Share Sale, Helen Louise Collins, Chief Medical Officer, Rule 10b5-1